APRILBIO is a research and development specialist enterprise that develops new drug candidates, transferring technology around the Phase 1 clinical trial stage to generate revenue through technology fees. We possess the 'antibody library' technology, which acquires new drug candidates with the ability to bind to desired target antigens, and the 'SAFA platform' technology, which enhances the serum half-life of therapeutic proteins.

SAFA TECHNOLOGY(Serum Albumin Fab-Associated) : High affinity anti-SA Fab from HuDVFab library / Determination of therapeutic effector proteins (Ab fragments, cytokines or hormones) / Production of fusion proteins by using gene cloning and protein expression system / In vivo administration of a fusion protein binding of fusion protein to SA in the body / Prolonged serum half-life of a SAFA fusion protein drug

Public

Biotech